A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria by Phillips, M, White, K, Kokkonda, S, Deng, X, White, J, El Mazouni, F, Marsh, K, Tomchick, D, Manjalanagara, K, Rudra, K, Wirjanata, G, Noviyanti, R, Price, R, Marfurt, J, Shackleford, D, Chiu, F, Campbell, M, Jimenez Diaz, M, Ferrer-Bazaga, S, Angulo-Barturen, I, Martínez-Martínez, M, Lafuente-Monasterio, M, Kaminsky, W, Silue, K, Zeeman, A, Kocken, C, Leroy, D, Blasco, B, Rossignol, E, Rueckle, T, Matthews, D, Burrows, J, Waterson, D, Palmer, M, Rathod, P, Charman, S

UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria by Brunschwig, C, Lawrence, N, Taylor, D, Abay, E, Njoroge, M, Basarab, GS, Le Manach, C, Paquet, T, Cabrera, D, Nchinda, AT, de Kock, C, Wiesner, L, Denti, P, Waterson, D, Blasco, B, Leroy, D, Witty, MJ, Donini, C, Duffy, J, Wittlin, S, White, KL, Charman, SA, Jiménez-Díaz, MB, Angulo-Barturen, I, Herreros, E, Gamo, FJ, Rochford, R, Mancama, D, Coetzer, TL, van der Watt, ME, Reader, J, Birkholtz, L-M, Marsh, KC, Solapure, SM, Vanaerschot, M, Fidock, DA, Fish, PV, Siegl, P, Smith, DA, Wirjanata, G, Noviyanti, R, Price, RN, Marfurt, J, Silue, KD, Street, LJ, Chibale, K